Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLI1 | P08151 | 1/20 | 0.64 |
| ▸ | GLI2 | P10070 | 1/20 | 0.64 |
| ▸ | FDFT1 | P37268 | 4/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | PTGES | O14684 | 1/20 | 0.53 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.51 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.51 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.51 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
| ▸ | CTSD | P07339 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17037435 | 0.90 | GLI1 (0.61) | GLI1GLI2FDFT1PTGESPLAAT3 | |
| SCHEMBL14521444 | 0.87 | CYP2D6 (0.61) | GLI1GLI2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL2772929 | 0.84 | FDFT1 (0.66) | GLI1GLI2FDFT1PLAAT3PLAAT5 | |
| SCHEMBL11533548 | 0.83 | GLI1 (0.81) | GLI1GLI2FDFT1CYP2D6KMT2A | |
| SCHEMBL7866857 | 0.82 | KMT2A (0.81) | CYP2D6CYP2C9CYP2C19KMT2A | |
| SCHEMBL10106169 | 0.82 | MTNR1A (0.68) | FDFT1AKR1C3 | |
| SCHEMBL9781817 | 0.81 | FDFT1 (0.59) | GLI1GLI2FDFT1CYP2D6PTGES | |
| Hydrochloric Acid SCHEMBL27729415 | 0.81 | KMT2A (0.78) | CYP2D6CYP2C9CYP2C19KMT2A | |
| SCHEMBL5354570 | 0.79 | FDFT1 (0.57) | GLI1GLI2FDFT1PLAAT3PLAAT5 | |
| SCHEMBL9352820 | 0.79 | FFAR1 (0.55) | FDFT1PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9586931-B2 | Triazolyl derivatives as Syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20150239866-A1 | TRIAZOLYL DERIVATIVES AS SYK INHIBITORS | MERCK CANADA INC. (CA) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239866-A1 | TRIAZOLYL DERIVATIVES AS SYK INHIBITORS | SYK, BTK, TYRO3 | GLI1 4207/4885GLI2 3274/4885FDFT1 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.